An insomnia treatment linked to sleepwalking and sleep driving should stay on the market according to the Australian Therapeutic Good Administration (TGA).
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including a new CEO at Patheon and appointments at Aesica.
Contract Research Organisation (CRO) Calvert Labs has launched a new iPhone “app” that lets customers track the progress of preclinical research projects with their mobile phones.
Germany’s Merck KGaA has completed its $7bn (€b5.2n) acquisition of Millipore, unveiling plans to target “high-growth, high-margin” bio-research and bio-production markets.
Rumour has it that French drug giant Sanofi Aventis is planning to make a $20bn (€16bn) acquisition in the US with speculation that biotechs like Allergan, Biogen Idec and Genzyme are among the targets.
Patheon attributes Q1 loss to charges and plant closure costs and says there has been “an encouraging increase in new sales activity” in calendar 2010.
Sanofi Aventis has revamped operations at its sterile injectables plant in Le Trait, France, adding three new production units that double syringe making capacity and diversify its vaccine manufacturing capability.
Sanofi-aventis is initiating the phased closing its manufacturing facility in Kansas, US, with complete shutdown expected to occur in 2012 and impact on 370 employees.
Sanofi-Aventis has moved to defend its long-acting diabetes treatment Lantus (insulin glargine) and says that recent research linking it to the development of cancer is of “poor quality.”
Sanofi Aventis will pay Pfizer €30m ($41m) for a former Exubera manufacturing plant in Frankfurt-Höchst, Germany that was due to be bought by inhaled insulin specialist MannKind.
Sanofi-Aventis has expanded its collaboration with Pilgrims to include its Dagenham, UK facility, which will now be guarded by the security services company.
Sanofi-Aventis is investing a further $90m in its Chinese manufacturing facility and performing “the world’s largest diabetes genotyping project” in partnership with the Chinese Diabetes Society.
French drug major Sanofi Aventis is in talks about taking over market leading Brazilian generics firm Medley, according to reports the country’s Valor Economico newspaper.
Ahead of the “open house” at its facility in Monteriggioni, Siena, Italian machining specialist Marchesini spoke with in-PharmaTechnologist.com about the new plant and its role in the firm's offering to the drug industry.
Rumours that Pfizer is looking into buying a large stake in
Sanofi-Aventis, which could be seen as a prelude to a full takeover
bid, has prompted a flurry of shareholder activity.
Sanofi-Aventis' disposable insulin pen SoloStar has been launched
across the US for use with the company's 24-hour basal insulin
Lantus (insulin glargine), despite patent infringement claims
emanating from fellow insulin...
Despite numerous media reports of an impending patent infringement
suit, Sanofi-Aventis has yet to formally hear anything from
plaintiff Novo Nordisk, who claims the French firm's SoloStar
insulin pen violates patents covering...
US diabetics will soon have a new alternative to the predominant
needle and syringe method of administering insulin, now that the
Food and Drug Administration (FDA) has granted marketing approval
to Sanofi-Aventis' Lantus SoloStar.
Sanofi-Aventis is gearing up for the European roll-out of a new
disposable insulin pen designed to address a broader spectrum of
patient needs than currently available injection devices.
Looking to expand its laboratory testing and consulting services,
PharmEng has acquired Rootlink Tecknic, a laboratory
instrumentation automated solution sales and service company based
in Toronto.
Looking to establish itself in Eastern Europe, French drug maker
Sanofi-Aventis has bought a 24.9 per cent stake in Czech generic
drug firm Zentiva for $514.7m (€430m).
French pharmaceutical company, Sanofi-Aventis, reported an increase
in sales for the fourth quarter with its vaccine business
continuing to impress. The company's performance precedes two
upcoming decisions later this year that...
Danish pharmaceutical company Novo Nordisk has filed a lawsuit
against France's Sanofi-Aventis, alleging that the latter has
infringed patent protection for an insulin injection system for
diabetes patients.
The creation of Sanofi-Aventis last year created a dent in its
second-quarter net profit as the French company looked to provide
good news to its investors. The drug maker managed to raise its
earnings target for the year and accelerated...
French public prosecutors have expanded their criminal
investigations into alleged accounting irregularities by specialty
chemicals maker Rhodia, with a raid on the country's Ministry of
Finance.
French chemicals company Rhodia, already facing two separate
investigations for alleged accounting irregularities and insider
trading, has become embroiled in further legal fights just as it
starts to lift itself out of financial...
News that B-MS has dropped out of an agreement to develop Basulin,
an improved formulation of insulin which was the subject of a $165
million deal - including $20 million upfront - between the two
companies last year.
French pharmaceutical group Sanofi-Synthelabo on Friday formally
announced the birth of Sanofi-Aventis, the world's third-largest
pharmaceutical company, ranking number one in Europe.
Switzerland's Novartis has decided to withdraw from any
negotiations with Aventis over a possible merger, after official
discussions with the latter and fellow French-based company
Sanofi-Synthelabo got underway.
Switzerland's Novartis has confirmed that it is interested in
joining with Aventis, but will not proceed with a formal bid unless
the French government draws back from its hostile stance on a
link-up, reports Phil Taylor.
The French government has embarked on a fact-finding exercise to
try to work out ways it can address the country's diminishing
standing as a centre for biopharmaceutical R&D.
Aventis could hang on to its 15 per cent stake in chemicals company
Rhodia under the terms of a new agreement with the European
Commission. The company will instead sell off its 49 per cent stake
in Wacker Chemie over the next several...
Sanofi's hostile bid for larger French rival Aventis may have been
rejected, but there are a number of arguments in favour of a link,
according to analyst Nicole Lamble at market research firm
Datamonitor.
French pharmaceutical company Sanofi-Synthelabo has launched a
hostile takeover bid for its larger rival Aventis, in a move which
would create a top three drug major.